Larimar Therapeutics (LRMR) Capital Expenditures Growth (3y) (2017 - 2025)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Capital Expenditures Growth (3y) (2017 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 23.70% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 0.24% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 23.48% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 63.07% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -45.93% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 29.63% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -16.79% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 27.08% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -21.16% |
| Dec 31, 2024 | 170.94% |
| Sep 30, 2024 | 28.82% |
| Jun 30, 2024 | 108.65% |
| Mar 31, 2024 | -61.42% |
| Dec 31, 2023 | -24.92% |
| Sep 30, 2023 | -58.74% |
| Mar 31, 2023 | -28.13% |
| Mar 31, 2022 | 108.71% |
| Dec 31, 2021 | -9.14% |
| Sep 30, 2021 | -25.45% |
| Jun 30, 2021 | -50.96% |
| Mar 31, 2021 | 591.74% |
| Dec 31, 2020 | 144.99% |
| Sep 30, 2020 | -25.31% |
| Mar 31, 2020 | 79.67% |
| Jun 30, 2019 | -56.10% |
| Mar 31, 2019 | -69.82% |
| Dec 31, 2018 | -68.14% |
| Sep 30, 2018 | -1.84% |